Neurology News

The correlation between age and contrast-enhancing lesions “is a general phenomenon” across the MS spectrum of disease, according to an analysis of four large, randomized controlled trials published in Neurology.

The AMA said today that the CPT code set has been updated to include codes for a third dose of the Moderna and Pfizer/BioNTech COVID-19 vaccines.

A transport policy for emergency medical services resulted in a substantial and swift increase in rates of endovascular therapy after acute ischemic stroke, according to findings from a single-center study published in JAMA Neurology.

Black adults reported experiencing discrimination or unfair judgment in health care settings at triple the rate of white adults and double the rate of Hispanic or “Latinx” adults, according to recent survey data.

Findings published recently in Journal of Medical Economics demonstrated that patients with focal seizures who began first adjunctive therapy with eslicarbazepine acetate vs. brivaracetam had considerably larger reductions in medical costs.

The FDA approved belzutifan for treatment of cancers associated with von Hippel-Lindau disease.

The FDA approved a new indication for Xywav for the management of idiopathic hypersomnia in adults, according to a press release from the agency.

A mounting body of evidence is showing that cognitive dysfunction in lupus is a legitimate complaint, according to a presenter at the 2021 Congress of Clinical Rheumatology-East.

The FDA placed a clinical hold on a phase 3 study designed to evaluate elivaldogene autotemcel, an investigational gene therapy, for the treatment of younger patients with cerebral adrenoleukodystrophy.

Patients with focal seizures who initiated first adjunctive therapy with eslicarbazepine acetate vs. brivaracetam had significantly larger reductions in medical charges, as well as in prescription charges unrelated to anti-seizure drugs.